NASDAQ · BDSX
Biodesix, Inc.
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
Loading market information…
NASDAQ · CTSO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cytosorbents Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cytosorbents Corporation’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.90. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cytosorbents Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 14, 2025 | -$0.02+98.75% vs estimate | $8.73M-3.11% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$0.60+40.0% vs estimate | $9.20M-10.24% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.80+33.33% vs estimate | $9.39M-7.72% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
$8.11-$0.31 (-3.68%)
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
$0.96-$0.05 (-4.53%)
Telomir Pharmaceuticals, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 38.97% below the high.
$1.57+$0.01 (+0.64%)
Spectral AI, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.14% below the high.
$2.77-$0.05 (-1.77%)
Sensus Healthcare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.54% below the high.
$0.92-$0.06 (-5.74%)
TELA Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
$1.89+$0.25 (+15.24%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.2% below the high.
$0.97+$0.11 (+12.96%)
NeuroOne Medical Technologies Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.15% below the high.
